New drug cocktail HRS-6209 shows promise in early breast cancer trial

NCT ID NCT06974929

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called HRS-6209, taken as a capsule, combined with either letrozole or another drug HRS-2189 in 80 women with breast cancer. The goal is to find a safe dose and see if the combination can shrink tumors. It is an early-stage trial, so the main focus is on safety and tolerability.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HRS-6209 (a drug taken by mouth) combined with either letrozole or HRS-2189
What this could lead to
If successful, this could point toward a new combination treatment option for breast cancer that may help shrink tumors or slow disease progression.
What could go wrong
This is an early-phase trial with only 80 participants, so it is primarily testing safety and dosing. The combination may not prove effective against breast cancer, and side effects could limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tianjin Medical University Cancer Institute and Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, 300060, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.